The White Biotechnology Market Report is Segmented by Type (Biofuels, Biomaterials, Biochemicals, and Industrial Enzymes), Application (Bioenergy, Pharmaceuticals, Food and Beverages, Animal Feed, and Other Applications), and Geography (North America, Europe, Asia-Pacific, South America, and Middle East and Africa). The Market Forecasts are Provided in Terms of Value (USD).

This statistic depicts a selection of global top biotechnology companies based on market capitalization as of June 18, 2025. At this point, U.S. biopharmaceutical manufacturer Eli Lilly was ranked first among such companies, with a market capitalization of *** billion U.S. dollars. Thus, Eli Lilly was also the most valuable company of the whole biotech-pharma industry. Global biotechnologyAbbVie is among the largest, mostly biotech-oriented companies in the world. In June 2025, AbbVie, a company based in the U.S., had a market capitalization of *** billion U.S. dollars. As of 2020, there were ***** companies in the United States dedicated to biotechnology, while, in comparison, Germany had around *** such companies. Biotech companies located in the San Francisco Area and in Los Angeles/Orange County generate the highest amount of biotech revenue within the United States. In the United States, medical biotechnology is a significant component of the entire biotech industry. Jobs in research, testing, and medical laboratories have increased significantly. Biotechnology is also commonly used in agriculture. Biotech crops in the United States accounts for more than half of the world’s total. With a total of **** million acres of corn crops in the United States, only *** million acres are considered non-biotech fields. Biotechnology also extends into the industrial sector, providing innovation for nanotechnology, enzymes, and biofuels.

• The global industry was valued at US$ 1.8 Bn in 2023
• It is expected to grow at a CAGR of 18.8% from 2024 to 2034 and reach US$ 13.1 Bn by the end of 2034

Market Introduction

Attribute	Detail
AI in Pharma and Biotech Market Drivers	Need to Have a Speedy Drug Development Gene Editing through AI Progression

Regional Outlook

Attribute	Detail
Leading Region	North America

AI in Pharma and Biotech Market Snapshot

Attribute	Detail
Market Size in 2023	US$ 1.8 Bn
Market Forecast (Value) in 2034	US$ 13.1 Bn
Growth Rate (CAGR)	18.8%
Forecast Period	2024-2034
Historical Data Available for	2020-2022
Quantitative Units	US$ Bn for Value
Market Analysis	It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis.
Competition Landscape	Market share analysis by company (2023) Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials
Format	Electronic (PDF) + Excel
Market Segmentation	Application Drug Discovery and Development Clinical Trials and Optimization Predictive Maintenance and Quality Control Drug Target Identification Disease Diagnosis & Prognosis Others End-user Pharmaceutical & Biotech Companies Academic & Contract Research Organizations Others
Regions Covered	North America Europe Asia Pacific Latin America Middle East & Africa
Countries Covered	U.S. Canada Germany U.K. France Italy Spain China India Japan Australia & New Zealand Brazil Mexico South Africa GCC
Companies Profiled	BenevolentAI SA Insilico Medicine Recursion Pharmaceuticals Atomwise Inc. Berg LLC Cloud Pharmaceuticals Deep Genomics Exscientia Schrödinger twoXar, Inc. Insitro
Customization Scope	Available Upon Request
Pricing	Available Upon Request

Biotechnology Market size is growing with a CAGR of 12.3% in the prediction period and it crosses USD 2,330.47 Bn by 2032, from USD 1,034.63 Bn in 2025.

The global biotechnology market size is valued at 1.57 trillion in 2024 and is poised to reach USD 8.01 trillion by 2035, representing a CAGR of 15.98% during the forecast period 2024-2035.

The global biotechnology market from USD 1.64 trillion in 2024 to reach unprecedented USD 5.85 trillion by 2034, powered by a revolutionary CAGR of 13.6% with cutting-edge therapeutic solutions.

Unlock data-backed intelligence on Vietnam Biotech Market, size at USD 1.5 billion in 2023, featuring industry trends and growth opportunities.

The Red Biotechnology Market Report is Segmented by Product (Vaccines [mRNA Vaccines, Viral Vector Vaccines, and More], Therapeutic Drugs [Monoclonal Antibodies, Recombinant Proteins, and More], and Diagnostics & Research Tools [Sequencing Reagents & Kits and More]), End-User (Biopharmaceutical Companies and More), Aand Geography (North America, Europe, and More). The Market Forecasts are Provided in Terms of Value (USD).

Biotechnology Market size was valued at USD 1023.92 Billion in 2024 and is projected to reach USD 2590.03 Billion by 2032, growing at a CAGR of 12.3% from 2026 to 2032.Global Biotechnology Market DriversTechnological Advancements: Rapid advances in technologies like as gene editing (e.g., CRISPR-Cas9), synthetic biology, and bioinformatics are propelling the biotechnology business. These advancements allow for more accurate and efficient manipulation of genetic material, promoting the development of new medicines, agricultural products, and industrial enzymes. The introduction of high-throughput sequencing and computational techniques is speeding research and development, lowered costs and cutting time-to-market for biotechnology goods. This technical advancement is accelerating progress in customized medicine, regenerative medicines, and bio-based manufacturing.Increasing Healthcare Needs: The increasing frequency of chronic diseases, aging populations, and the global burden of infectious diseases are all driving a strong need for sophisticated medical treatments. Biotechnology has exciting opportunities for producing targeted medicines, vaccines, and diagnostic tools. The rising prevalence of diseases including cancer, diabetes, and unusual genetic illnesses needs novel treatments, many of which are being produced through biotechnological research.Government Support and Regulatory Frameworks: Supportive government policies, funding, and favorable regulatory frameworks are key drivers of the biotechnology market. Many governments recognize biotechnology's potential to address significant health, agricultural, and environmental issues, prompting increased funding in R&D programs. Regulatory organizations are also expediting the approval process for biotech products, fostering innovation while assuring safety and efficacy. Public-private collaborations and funding for biotech firms and research institutes are creating a favorable climate for the growth of the biotechnology sector.Evolving Consumer Preferences: Consumers are increasingly valuing health, well-being, and sustainability, which is fueling demand for biotech technologies. In the food and agriculture industries, there is a rising preference for genetically modified crops that have superior nutritional value, flavor, and yields. In healthcare, patients want individualized and precision medication alternatives, which biotechnology may give. The trend for natural and eco-friendly products is driving the use of biotechnology in a variety of consumer items, including cosmetics and dietary supplements. This shift in consumer behavior encourages businesses to invest in biotechnology research and product development to suit changing market demands.

In 2022, biotechnology companies in Germany received around 475 million euros from risk capital. Since 2011 the amount of money invested in biotechnology companies has rapidly increased. 2020 and 2021 were by far the most successful years for funding.

Nanotechnology in Biotech Market Size is expected to reach USD 13.9 billion by 2033 from USD 5.6 billion in 2023, growing at a CAGR of 9.5%.

Biotechnology is becoming an increasingly important part of product development in a variety of sectors, with businesses using biotech applications to address many social and economic issues, including human health, food security and alternative fuels. Several companies have reached commercial readiness, with robust product pipelines and support from international partners improving their attractiveness to investors. While human therapeutics companies continue to dominate the industry, agricultural technology and food technology companies are gaining momentum. New funding sources are helping to drive industry growth. The COVID-19 pandemic has also influenced the industry's operating environment, with several biotech players at the frontline of COVID-19 research, prevention and treatment. Overall, industry revenue is expected to expand at an annualised 2.4% over the five years through 2024-25, to total $12.3 billion. This trend includes anticipated revenue growth of 2.3% in 2024-25. In the coming years, a greater number of biotechs are set to generate revenue and shift towards profitability. An ageing population will drive demand for new, targeted biotech products that focus on unmet needs. Australia's emerging medicinal cannabis market may drive growth for both agricultural and pharmaceutical biotech companies, as will Australia's developing regenerative medicine sector. The need for sustainable and environmentally friendly bioenergy will support advances in industrial and environmental biotechnology. In the wake of the COVID-19 pandemic, local biotechs stand to benefit from government-led efforts to enhance Australia's sovereign capabilities in specialised Good Manufacturing Practice capabilities and infrastructure within the wider biotechnology ecosystem. A supportive and efficient operating environment, sustained by favourable government policies and funding, will remain crucial for the industry’s development. To this end, the industry is calling for the development of a cohesive national strategy specific to the wider life sciences sector, supported by a Life Sciences Council. Industry-led efforts, as set out in Biotechnology Blueprint: A Decadal Strategy for the Australian Biotechnology Industry, will also help shape the industry going forwards. In view of these favourable variables, industry revenue is forecast to climb by 4.0% annualised over the five years through 2029-30 to $14.9 billion.

Explore insights from Market Research Intellect's Ai For Pharma And Biotech Market Report, valued at USD 5.1 billion in 2024, expected to reach USD 15.2 billion by 2033 with a CAGR of 16.5% during 2026-2033.Uncover opportunities across demand patterns, technological innovations, and market leaders.

The Biotechnology Market will grow from USD 1.45 Trillion in 2024 to USD 2.99 Trillion by 2030 at a 12.85% CAGR.

Pages	180
Market Size	2024 USD 1.45 Trillion
Forecast Market Size	USD 2.99 Trillion
CAGR	12.85%
Fastest Growing Segment	Biopharmaceuticals
Largest Market	North America
Key Players	['Novo Nordisk A/S', 'Regeneron Pharmaceuticals Inc.', 'Amgen, Inc.', 'CSL Limited', 'Gilead Sciences, Inc.', 'Celgene Corporation', 'Biogen Inc.', 'Vertex Pharmaceuticals, Inc.', 'Seagen Inc.', 'Genmab A/S']

The global biotechnology market size is projected to grow from USD 1,650 billion in 2025 to USD 5,220 billion by 2034, exhibiting a CAGR of 13.67%.
Report Scope:

Report Metric	Details
Market Size in 2025	USD 1,650 Billion
Market Size in 2026	USD 1,870 Billion
Market Size in 2034	USD 5,220 Billion
CAGR	13.67% (2026-2034)
Base Year for Estimation	2025
Historical Data	2022-2024
Forecast Period	2026-2034
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends
Segments Covered	By Technology,By Applications,By Region.
Geographies Covered	North America, Europe, APAC, Middle East and Africa, LATAM,
Countries Covered	U.S., Canada, U.K., Germany, France, Spain, Italy, Russia, Nordic, Benelux, China, Korea, Japan, India, Australia, Taiwan, South East Asia, UAE, Turkey, Saudi Arabia, South Africa, Egypt, Nigeria, Brazil, Mexico, Argentina, Chile, Colombia,

Introduction

Global Agricultural Biotechnology Market size is expected to be worth around US$ 232 Billion by 2033, from US$ 111 Billion in 2023, growing at a CAGR of 7.86% during the forecast period from 2024 to 2033. In 2023, North America led the market, achieving revenue of US$ 39.2 Billion.

Biotechnological innovations are integral to advancing sustainable agriculture, enhancing soil health, and boosting crop productivity. Biofertilizers and biopesticides play a key role in improving yields while minimizing environmental impacts. Furthermore, genetic advancements in crops and livestock production enhance disease resistance and production efficiency, addressing the growing global demand for food.

The industry is actively responding to climate change by developing resilient crop varieties capable of withstanding extreme weather and resource shortages, such as drought-resistant crops. This progress is supported by digital agricultural tools, including precision farming technologies, which optimize resource utilization and improve risk management in farming practices.

Technological innovations are also critical in reducing food waste across supply chains. Improved monitoring systems and enhanced logistics, driven by biotechnology and digital solutions, help minimize losses from production to consumption. Additionally, the industry’s growth is supported by favorable policies and economic incentives promoting sustainable practices and providing better market access for farmers.

Recent developments in agricultural biotechnology highlight a strong focus on innovation. Corteva’s collaboration with Pairwise, supported by a $25 million investment, focuses on gene-editing technologies to improve crop resilience. BASF has established a new fermentation plant dedicated to biological crop protection, while ADAMA is expanding its research and development capabilities in Shanghai. Bayer AG’s strategic shift toward regenerative agriculture, targeting a market potential of over €100 billion, underscores the sector’s promising future.

https://market.us/wp-content/uploads/2019/06/global-agricultural-biotechnology-market.jpg" alt="global agricultural biotechnology market" class="wp-image-99146">

Check Market Research Intellect's Biotech Drug Market Report, pegged at USD 500 billion in 2024 and projected to reach USD 800 billion by 2033, advancing with a CAGR of 6.5% (2026-2033).Explore factors such as rising applications, technological shifts, and industry leaders.

AI in Biotech Market Outlook

According to our latest research, the global AI in Biotech market size reached USD 3.4 billion in 2024, demonstrating robust momentum across the biotechnology sector. The market is expected to grow at a CAGR of 28.2% from 2025 to 2033, with the forecasted market size projected to reach USD 31.1 billion by 2033. This substantial growth is driven by the rapid adoption of artificial intelligence technologies in drug discovery, genomics, clinical trials, and personalized medicine, as organizations seek to accelerate research timelines, reduce costs, and improve patient outcomes. As per our latest research, this market’s expansion is underpinned by increasing investments from both public and private sectors, as well as a growing ecosystem of AI-driven biotech startups and collaborations.

The primary growth driver for the AI in Biotech market is the urgent need to optimize drug discovery processes. Traditional drug development is notoriously time-consuming and expensive, often taking over a decade and billions of dollars to bring a new drug to market. AI-powered platforms are now enabling pharmaceutical and biotechnology companies to rapidly analyze massive datasets, identify promising drug candidates, and predict their efficacy and safety profiles with unprecedented accuracy. This not only accelerates the time-to-market for new therapies but also significantly reduces R&D costs, making drug development more accessible and scalable. The rise of big data analytics, coupled with advancements in machine learning algorithms, has further amplified the impact of AI in transforming the biotech landscape.

Another key factor fueling market growth is the integration of AI in genomics and personalized medicine. The ability to sequence and interpret genetic data at scale has opened new frontiers in understanding disease mechanisms and tailoring treatments to individual patients. AI algorithms are now being used to identify genetic mutations, predict disease risk, and suggest personalized therapeutic strategies, driving a paradigm shift from one-size-fits-all treatments to precision medicine. This has profound implications for patient care, particularly in oncology, rare diseases, and chronic conditions, where targeted therapies can dramatically improve outcomes. The convergence of AI, genomics, and biotechnology is thus creating a powerful synergy that is reshaping the future of healthcare.

The expanding application of AI in clinical trials and diagnostics is also contributing significantly to market growth. Clinical trials are a critical bottleneck in the drug development pipeline, often plagued by inefficiencies in patient recruitment, data management, and outcome analysis. AI-driven solutions are streamlining these processes by identifying suitable candidates, monitoring patient adherence, and analyzing trial data in real time. Similarly, AI-enabled diagnostic tools are enhancing the accuracy and speed of disease detection, enabling earlier interventions and better prognosis. These advancements are not only improving operational efficiency but also increasing the likelihood of successful trial outcomes, thereby boosting investor confidence and fueling further innovation in the AI in Biotech market.

From a regional perspective, North America continues to dominate the AI in Biotech market, accounting for the largest share in 2024. This leadership is attributed to the presence of a mature healthcare infrastructure, significant investments in R&D, and a high concentration of AI and biotech companies. Europe follows closely, driven by supportive regulatory frameworks and strong government initiatives to foster innovation. Meanwhile, the Asia Pacific region is emerging as a high-growth market, propelled by increasing healthcare expenditures, a burgeoning biotech industry, and a rapidly growing pool of skilled AI professionals. Latin America and the Middle East & Africa are also witnessing gradual adoption, although challenges related to infrastructure and funding persist. Overall, the global landscape is characterized by intense competition, cross-border collaborations, and a relentless drive towards digital transformation in biotechnology.

Component Analysis

The AI in Biotech market is segmented by component into Software, Hardware, and Services, each playing a critical role in the overall ecosystem. The software segment holds the largest market share, driven by the proliferation of advanced AI algorit

AI in Biotech Market Outlook

According to our latest research, the global AI in Biotech market size reached USD 4.2 billion in 2024, reflecting a robust upward trajectory driven by rapid technological advancements and increasing adoption of artificial intelligence in life sciences. The market is forecasted to grow at a remarkable CAGR of 29.1% from 2025 to 2033, projecting a value of USD 43.8 billion by 2033. This accelerated growth is primarily fueled by the surging demand for faster drug discovery processes, precision medicine, and the integration of AI-driven analytics across various biotech applications. As per our latest research, the convergence of AI and biotechnology is fundamentally transforming research and development, diagnostics, and therapeutics, positioning the sector for unprecedented expansion in the coming decade.

One of the central growth factors propelling the AI in Biotech market is the increasing complexity and volume of biological data generated through genomics, proteomics, and clinical research. The sheer scale of data being produced necessitates advanced computational tools for effective analysis, pattern recognition, and hypothesis generation. AI-powered platforms excel at extracting actionable insights from vast datasets, enabling researchers to identify novel biomarkers, therapeutic targets, and disease pathways with greater speed and accuracy than traditional methods. This capability not only accelerates the drug discovery and development timeline but also reduces costs and enhances the probability of clinical success, making AI indispensable to modern biotechnology workflows.

Another significant driver is the growing emphasis on personalized medicine, where AI algorithms are used to tailor treatments based on individual genetic profiles, lifestyle factors, and environmental influences. The integration of AI in genomics and diagnostics allows for the identification of patient-specific mutations and disease susceptibilities, leading to more precise and effective interventions. Pharmaceutical and biotechnology companies are increasingly leveraging AI to stratify patient populations, optimize clinical trial design, and predict therapeutic responses, thereby improving outcomes and minimizing adverse effects. This shift toward data-driven, patient-centric care is expected to further stimulate demand for AI solutions across the biotech value chain.

Moreover, the global healthcare ecosystem's response to emerging infectious diseases, such as COVID-19, has underscored the critical role of AI in accelerating vaccine and therapeutic development. AI-driven platforms facilitate rapid screening of molecular compounds, simulation of biological interactions, and prediction of drug efficacy, significantly shortening the time required to bring new solutions to market. The ongoing digital transformation in healthcare, coupled with increased investments from public and private sectors, has created a fertile environment for AI innovation in biotechnology. As regulatory agencies adapt to the evolving technological landscape, the adoption of AI-powered tools in clinical trials, diagnostics, and regulatory submissions is expected to surge, paving the way for sustained market growth.

Biomarker Discovery AI is becoming an essential component in the biotechnology sector, particularly in the realm of personalized medicine. By leveraging advanced machine learning algorithms, AI systems can sift through vast amounts of biological data to identify potential biomarkers that indicate disease presence or progression. This capability is transforming how researchers approach diagnostics and treatment planning, offering the potential for earlier detection and more targeted therapies. As the technology matures, Biomarker Discovery AI is expected to play a pivotal role in the development of precision medicine, enabling healthcare providers to tailor interventions to individual patient profiles, thereby improving outcomes and reducing healthcare costs.

From a regional perspective, North America continues to dominate the AI in Biotech market, owing to its well-established ecosystem of pharmaceutical giants, biotech startups, and academic research institutions. The United States, in particular, benefits from substantial R&D investments, favorable regulatory frameworks, and a strong talent pool in both AI and life sciences.

In 2023, there were 139 medical biotechnology companies in Germany. This was an increase compared to the previous year, and the trend shows that over the past 10 years the number of companies in this field has increased.